2. UroToday Home
  3. Conference Highlights
  4. 11th International Symposium on Targeted Alpha Therapy, TAT-11

TAT-11: The Therapeutic Potential of Anti-HER2 2Rs15d Nanobody Labeled with Ac-225 – An In Vitro and In Vivo Evaluation

Ottawa, ON, Canada (UroToday.com) HER2 is expressed in many types of tumors. In the studies described here the effect on tumor growth of the anti-HER2 nanobody, Nb 2Rs15d labeled with Ac225 both in vitro and in female athymic nude mice subcutaneously xenografted with SKOV-3 and MDAMB-231 tumors. Tumor uptake of the Ac225_DOTA-Nb 2Rs15d was high in the SKOV-3 mice 1 hour after injection.

Kidney uptake could be reduced by co-injection of 150 mg/kg of Gelofusine. A significant improvement in median survival of 83 days compared to 49 days with controls. Median survival could be improved to 97 days with the combination of Ac225_DOTA-Nb 2Rs15d and trastuzumab.


Presented by: Marek Pruszynski, PhD, Institute of Nuclear Chemistry and Technology, Centre of Radiochemistry and Nuclear Chemistry, Warsaw, Poland

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada